1ADAM R A, ADAM Y G. Malignant ascites: past, present, and future[J]. J Am Coll Surg, 2004, 198: 999-1011.
2SMITH E M, JAYSON G C. The current and future management of malignant ascites [J]. Clin Oncol, 2003,15 : 59- 72.
3BEN DAVIDSON, ITAI SHAFAT, BJoRN RISBERG. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma[J]. Gynecologic Oncology, 2007,104:311-319.
4STEPHENSON J, GILBERT J. The development of clinical guidelines on paracentesis for ascites related to malignancy[J]. Palliat Med, 2002,169: 213-218.
5MCNAMARA P. Paracentesis-an effective method of symptom control in the palliative care setting[J]. Palliat Med, 2000,14 : 62- 64.
6BECKER G,GALANDI D, BLUM H E. Malignant ascites: Systematic review and guideline for treatment [J]. European J Cancer, 2006,42 : 589- 597.
7RICHARD H M, COLDWELL D M, BOY-KRANIS R L, et al. Pleurex tunneled catheter in the management of malignant ascites[J]. J Vase Interv Radiol, 2001,12:373-375.
8PHILLIPS W T,MEDINA L A, KLIPPER R, et al. A novel approach for the increased delivery of pharmaceutical agents to peritoneum and associated lymph nodes[J]. J Pharmacol Exp Ther, 2002,303 : 11- 16
9GAMUSZEK P, LICIANSKA I, SKIEISKI J S, et al. Biological investigation of the platinum( Ⅱ )-[ * I] iodohistamine complexes of potential synergistic anticancer activity[J]. Nucl Med Biol, 2002,29 : 169- 175.
10LOGGIE B W, FLEMING R A, RICHARD P D, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma[J]. Am Surg , 2001,67 : 999-1001.
8[1]Vincent T De Vita, Jr Samuel Hellman, Steven A Rosenberg. Cancer-principles and Practice of Oncology. J Clin Oncol, 1997, 5:2695
9[2]Markman M, Howeii SB, Lucas WE, et al. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies prcipally confined to the peritoneal cavity. J Clin 0nco1,1984,2: 1321
